Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Dogwood Therapeutics initiated a Phase 2b long-term extension study of Halneuron®, evaluating its safety and efficacy over 12 additional weeks to support upcoming FDA submissions and planned Phase 3 trials for chemotherapy-induced neuropathic pain (CINP). Initial 4-week Phase 2b results showed positive pain reduction effects, reinforcing the potent…